- Home
- FNGR vs BMEA Comparison
FNGR vs BMEA Comparison
Compare FNGR & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNGR
- BMEA
- Stock Information
- Founded
- FNGR 2016
- BMEA 2017
- Country
- FNGR Singapore
- BMEA United States
- Employees
- FNGR N/A
- BMEA N/A
- Industry
- FNGR Computer Software: Prepackaged Software
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- FNGR Technology
- BMEA Health Care
- Exchange
- FNGR Nasdaq
- BMEA Nasdaq
- Market Cap
- FNGR 95.6M
- BMEA 114.3M
- IPO Year
- FNGR N/A
- BMEA 2021
- Fundamental
- Price
- FNGR $1.56
- BMEA $1.96
- Analyst Decision
- FNGR
- BMEA Strong Buy
- Analyst Count
- FNGR 0
- BMEA 10
- Target Price
- FNGR N/A
- BMEA $15.70
- AVG Volume (30 Days)
- FNGR 208.0K
- BMEA 614.1K
- Earning Date
- FNGR 10-14-2025
- BMEA 10-28-2025
- Dividend Yield
- FNGR N/A
- BMEA N/A
- EPS Growth
- FNGR N/A
- BMEA N/A
- EPS
- FNGR N/A
- BMEA N/A
- Revenue
- FNGR $35,692,374.00
- BMEA N/A
- Revenue This Year
- FNGR N/A
- BMEA N/A
- Revenue Next Year
- FNGR N/A
- BMEA N/A
- P/E Ratio
- FNGR N/A
- BMEA N/A
- Revenue Growth
- FNGR 11.55
- BMEA N/A
- 52 Week Low
- FNGR $1.03
- BMEA $1.29
- 52 Week High
- FNGR $5.20
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- FNGR 47.10
- BMEA 55.83
- Support Level
- FNGR $1.50
- BMEA $1.86
- Resistance Level
- FNGR $1.66
- BMEA $2.11
- Average True Range (ATR)
- FNGR 0.12
- BMEA 0.12
- MACD
- FNGR 0.01
- BMEA 0.01
- Stochastic Oscillator
- FNGR 27.85
- BMEA 56.38
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.